OncLive SOSS

Authors

Thomas Martin, MD, University of California San Francisco

Latest:

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Regis Peffault de Latour, MD, PhD

Latest:

Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

Noah Merin, MD, PhD

Latest:

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center

Latest:

Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL Management

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

Steven L. Spitalnik, MD

Latest:

Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic Malignancies

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.

Zev A. Wainberg, M.D. Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program

Latest:

Improving outcomes in metastatic pancreatic cancer

Pancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.

Latest:

Dr Chen on the Evolution of Novel Therapies in Breast Cancer

Dawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center at Columbia University

Latest:

Rapid Readouts: Updated Results From KX-ORAX-001 Study

George Simon, MD, FACP, FCCP

Latest:

Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With Cancer

George Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.

Latest:

Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid Biopsies

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

Giselle Sholler, MD

Latest:

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Parul N Barry, MD

Latest:

Dr Barry on the Rationale for Using Partial Breast Irradiation in Breast Cancer Management

Parul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.

Emre Yekeduz, MD

Latest:

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Helen Ajufo, MD

Latest:

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

James H. Doroshow, MD

Latest:

Dr. Doroshow on Increasing Patient Accrual to Clinical Trials During the COVID-19 Pandemic

James H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.

OncLive Article with Dr. Erika Hamilton

Francesco Maura, MD

Latest:

Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple Myeloma

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Laahn Ho Foster, MD

Latest:

Dr Foster on Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma After Transplant

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Jeremy Force, DO

Latest:

Dr. Force on the Efficacy of Trastuzumab Deruxtecan in the DESTINY-Breast02 Trial for HER2+ Breast Cancer

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Jun Zhang, MD, PhD, University of Kansas Medical Center

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer